Unknown PHASE2 INTERVENTIONAL NCT01144988

Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma (AVIRMA01-09)

An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas

Sponsor: Medical University Innsbruck

Conditions Recurrent Malignant Glioma

Interventions Bevacizumab / Irinotecan

Updated 5 times since 2017 Last updated: Aug 1, 2011 Started: Mar 31, 2010 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01144988, this PHASE2 trial focuses on Recurrent Malignant Glioma and remains ongoing. Sponsored by Medical University Innsbruck, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University Innsbruck
Roche, Austria

Data source: Medical University Innsbruck

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Innsbruck, Austria
• Salzburg, Austria